fluconazole has been researched along with Nail Fungus in 114 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Systemic treatment of onychomycosis is based these last years on the new drug utilization aiming to decrease the length of the treatment and secondary effects particularly with fluconazole." | 9.12 | [Fluconazole and treatment of onychomycosis. About 86 cases]. ( Ben Osman Dhahril, A; Bouassida, S; Denguezli, M; Doss, N; El Euch, D; Ezzine, N; Kourda, M; Mokhtar, I; Nouira, R; Ridha Kamoun, M; Turki, H, 2006) |
| "In order to assess the safety and efficacy of once-weekly fluconazole orally (100, 150, or 300 mg) with once-a-day topical application of 1% ketoconazole cream in the treatment of onychomycosis in Japan, 121 patients were assigned to one of three fluconazole dosages (100, 150, or 300 mg) and took fluconazole orally, once weekly, for 12 months or until a complete cure was achieved." | 9.11 | Combination therapy of once-weekly fluconazole (100, 150, or 300 mg) with topical application of ketoconazole cream in the treatment of onychomycosis. ( Chen, X; Hiruma, M; Ogawa, H; Shiraki, Y, 2004) |
| "In this open, randomized and comparative study, the safety and efficacy of systemic fluconazole, itraconazole and terbinafine was investigated in 50 patients with distal subungual toenail onychomycosis diagnosed clinically and mycologically." | 9.10 | An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. ( Akar, A; Arca, E; Gür, AR; Kurumlu, Z; Taştan, HB, 2002) |
| "To determine the cost effectiveness of terbinafine (Lamisil) tablets compared with fluconazole (Diflucan) capsules in the treatment of patients with toenail onychomycosis." | 9.10 | Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. ( Pekurinen, M; Salo, H, 2002) |
| "In a randomized, double-blind, double-placebo, multicentre study, terbinafine 250 mg daily for 12 weeks was compared with fluconazole 150 mg once weekly for 12 or 24 weeks in the treatment of onychomycosis." | 9.09 | A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. ( Havu, V; Heikkilä, H; Kuokkanen, K; Nuutinen, M; Rantanen, T; Saari, S; Stubb, S; Suhonen, R; Turjanmaa, K, 2000) |
| "Thirty-four patients with collagen diseases suffering from onychomycosis were treated with fluconazole and showed remarkable improvement." | 9.08 | [Effects of fluconazole on onychomycosis in the patients with collagen diseases]. ( Iwamoto, I; Izumi, H; Nawata, Y; Otawa, M; Sueishi, M; Sugiyama, T; Sumida, T; Takabayashi, K; Tanabe, E; Tomioka, H, 1995) |
| "Determinations of plasma and fingernail concentrations of fluconazole were performed as part of a larger study comparing the safety and efficacy of once-weekly fluconazole (150, 300, and 450 mg) to placebo in the treatment of distal subungual onychomycosis of the fingernails caused by dermatophytes." | 9.08 | Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. ( Babel, D; Breneman, D; Bucko, AD; Drake, L; Elewski, BE; Ellis, CN; Friedman, D; Hanifin, JM; Hilbert, J; Kang, S; Katz, HI; Leyden, JJ; Ling, MR; Martin, AG; McDonald, CJ; Morman, MR; Muglia, J; Pariser, DM; Pariser, RJ; Rich, P; Savin, RC; Scher, RK; Stewart, DM; Tschen, EH; Webster, G, 1998) |
| "The purpose of this study was to compare the efficacy and safety of three different doses of fluconazole (150, 300, and 450 mg) given orally once weekly to that of placebo in the treatment of distal subungual onychomycosis of the toenail caused by dermatophytes." | 9.08 | Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. ( Aly, R; Breneman, D; Bucko, AD; Elewski, BE; Feingold, DS; Greer, DL; Konnikov, N; Levine, N; Lowe, NJ; Morman, MR; Odom, RB; Pinnell, S; Rich, P; Savin, RC; Scher, RK; Shupack, JL; Smith, EB; Tschen, EH, 1998) |
| "Preliminary clinical data suggest that fluconazole is effective in the treatment of patients with onychomycosis." | 9.08 | Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. ( Aly, R; Breneman, D; Bucko, AD; Elewski, BE; Feingold, DS; Greer, DL; Hilbert, J; Konnikov, N; Levine, N; Lowe, NJ; Morman, MR; Odom, RB; Pinnell, S; Rich, P; Savin, RC; Scher, RK; Shupack, JL; Smith, EB; Tschen, EH, 1998) |
| "The purpose of this study was to assess the safety and efficacy of oral fluconazole 150, 300, and 450 mg administered once weekly compared with placebo in the treatment of distal subungual onychomycosis of the fingernail caused by dermatophytes." | 9.08 | Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. ( Babel, D; Breneman, D; Bucko, AD; Drake, L; Elewski, BE; Ellis, CN; Greer, DL; Hanifin, JM; Kang, S; Katz, HI; Leyden, JJ; Ling, MR; Martin, AG; McDonald, CJ; Morman, MR; Muglia, J; Pariser, DM; Pariser, RJ; Rich, P; Savin, RC; Scher, RK; Shupack, JL; Stewart, DM; Tschen, EH; Webster, G, 1998) |
| "The purpose of this study was to evaluate three different durations of once-weekly fluconazole for the treatment of onychomycosis of the toenail caused by dermatophytes." | 9.08 | Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. ( Asarch, RG; Babel, D; Bergfeld, WF; Cook, J; Drake, L; Eaglstein, WH; Falanga, V; Falo, L; Hanifin, JM; Jarratt, MT; Kalivas, J; Katz, HI; Lebwohl, MG; Leyden, JJ; Ling, MR; Martin, AG; Monroe, EW; Pariser, DM; Pariser, R; Stewart, DM; Swinyer, LJ; Tharp, M; Thiers, BH; Weinstein, GD; Young, MR, 1998) |
| "Fluconazole could be an alternative to terbinafine and itraconazole for onychomycosis treatment." | 8.89 | Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment. ( Drummond-Main, C; Gupta, AK; Paquet, M, 2013) |
| "To evaluate the efficacy of fluconazole for the treatment of onychomycosis." | 8.85 | Efficacy of fluconazole for the treatment of onychomycosis. ( Brown, SJ, 2009) |
| "Recently a novel topical nail lacquer, ciclopirox solution 8%, has been approved for the treatment of onychomycosis." | 8.80 | Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. ( Gupta, AK, 2000) |
| "It is concluded that the safranal can be successfully used as a safe and potential permeation enhancer to enhance the transungual delivery of fluconazole for the treatment of onychomycosis." | 8.12 | Investigation on utility of some novel terpenes on transungual delivery of fluconazole for the management of onychomycosis. ( Adin, SN; Ali, A; Aqil, M; Gupta, I; Mujeeb, M; Sultana, Y, 2022) |
| "Fusarium species have emerged as an important human pathogen in skin disease, onychomycosis, keratitis and invasive disease." | 7.85 | Genetic diversity and antifungal susceptibility of Fusarium isolates in onychomycosis. ( Corrêa, C; Fuentefria, AM; Goldani, LZ; Heidrich, D; Rosa, PD; Scroferneker, ML; Vettorato, G, 2017) |
| "To evaluate the in vitro antifungal activity of itraconazole, fluconazole, terbinafine and voriconazole against isolates taken from patients with onychomycosis." | 7.76 | In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. ( Bueno, JG; Gallego, M; Martinez, C; Mesa, AC; Sanclemente, G; Zapata, B, 2010) |
| "The aims of this study were to report the high prevalence of onychomycosis by Fusarium spp." | 7.74 | Fusarium spp. as agents of onychomycosis in immunocompetent hosts. ( Guilhermetti, E; Shinobu, CS; Svidzinski, TI; Takahachi, G, 2007) |
| "Using a reference microdilution method, we studied the antifungal susceptibility to voriconazole and fluconazole of 304 clinical isolates from four species of onychomycosis-causing dermatophytes, 196 isolates of dermatophytes not related to nail infection as well as Scopulariopsis brevicaulis, Fusarium spp." | 7.74 | In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. ( Cárdenes, CD; Carrillo-Muñoz, AJ; del Valle, O; Estivill, D; Giusiano, G; Guardia, C; Guarro, J; Quindós, G; Rodríguez, V, 2007) |
| "Our purpose was to evaluate the intermittent use of fluconazole (either once-weekly or alternate-day dosing) without concurrent nail avulsion in patients with moderate to severe onychomycosis." | 7.69 | Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. ( Assaf, RR; Elewski, BE, 1996) |
| "We report a case of fingernail onychomycosis in an immunosuppressed renal transplant patient who was successfully treated with once-weekly fluconazole therapy." | 7.68 | Onychomycosis: successful treatment with once-weekly fluconazole. ( Nahass, GT; Sisto, M, 1993) |
| "Fluconazole was well tolerated and side effects were negligible." | 6.77 | A comparative evaluation of combination therapy of fluconazole 1% and urea 40% compared with fluconazole 1% alone in a nail lacquer for treatment of onychomycosis: therapeutic trial. ( Bassiri-Jahromi, S; Ehsani, AH; Jamshidi, B; Mirshams-Shahshahani, M, 2012) |
| "Fluconazole (100 mg/day) was administered from April 8, 2006." | 5.35 | [A case of nail candidiasis with severe deformities treated with oral fluconazole]. ( Ito, Y; Kobayashi, M; Sei, Y; Soude, E; Sukegawa, N; Takahashi, E, 2008) |
| " An adverse function questionnaire was used on a monthly basis to assess patient tolerance." | 5.29 | An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. ( Lackland, D; Schneider, E; Sealy, DP; Smith, SW, 1995) |
| "Systemic treatment of onychomycosis is based these last years on the new drug utilization aiming to decrease the length of the treatment and secondary effects particularly with fluconazole." | 5.12 | [Fluconazole and treatment of onychomycosis. About 86 cases]. ( Ben Osman Dhahril, A; Bouassida, S; Denguezli, M; Doss, N; El Euch, D; Ezzine, N; Kourda, M; Mokhtar, I; Nouira, R; Ridha Kamoun, M; Turki, H, 2006) |
| "In order to assess the safety and efficacy of once-weekly fluconazole orally (100, 150, or 300 mg) with once-a-day topical application of 1% ketoconazole cream in the treatment of onychomycosis in Japan, 121 patients were assigned to one of three fluconazole dosages (100, 150, or 300 mg) and took fluconazole orally, once weekly, for 12 months or until a complete cure was achieved." | 5.11 | Combination therapy of once-weekly fluconazole (100, 150, or 300 mg) with topical application of ketoconazole cream in the treatment of onychomycosis. ( Chen, X; Hiruma, M; Ogawa, H; Shiraki, Y, 2004) |
| "To determine the cost effectiveness of terbinafine (Lamisil) tablets compared with fluconazole (Diflucan) capsules in the treatment of patients with toenail onychomycosis." | 5.10 | Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. ( Pekurinen, M; Salo, H, 2002) |
| "In this open, randomized and comparative study, the safety and efficacy of systemic fluconazole, itraconazole and terbinafine was investigated in 50 patients with distal subungual toenail onychomycosis diagnosed clinically and mycologically." | 5.10 | An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. ( Akar, A; Arca, E; Gür, AR; Kurumlu, Z; Taştan, HB, 2002) |
| "The uptake of the antimycotic agent fluconazole in finger and toe nail following various treatment schedules was investigated in order to characterize the pharmacokinetic basis for the systemic treatment of onychomycosis with fluconazole." | 5.09 | The uptake of fluconazole in finger and toe nails. ( Laufen, H; Schumacher, T; Wildfeuer, A; Yeates, RA; Zimmermann, T, 1999) |
| "In a randomized, double-blind, double-placebo, multicentre study, terbinafine 250 mg daily for 12 weeks was compared with fluconazole 150 mg once weekly for 12 or 24 weeks in the treatment of onychomycosis." | 5.09 | A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. ( Havu, V; Heikkilä, H; Kuokkanen, K; Nuutinen, M; Rantanen, T; Saari, S; Stubb, S; Suhonen, R; Turjanmaa, K, 2000) |
| "Preliminary clinical data suggest that fluconazole is effective in the treatment of patients with onychomycosis." | 5.08 | Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. ( Aly, R; Breneman, D; Bucko, AD; Elewski, BE; Feingold, DS; Greer, DL; Hilbert, J; Konnikov, N; Levine, N; Lowe, NJ; Morman, MR; Odom, RB; Pinnell, S; Rich, P; Savin, RC; Scher, RK; Shupack, JL; Smith, EB; Tschen, EH, 1998) |
| "The purpose of this study was to compare the efficacy and safety of three different doses of fluconazole (150, 300, and 450 mg) given orally once weekly to that of placebo in the treatment of distal subungual onychomycosis of the toenail caused by dermatophytes." | 5.08 | Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. ( Aly, R; Breneman, D; Bucko, AD; Elewski, BE; Feingold, DS; Greer, DL; Konnikov, N; Levine, N; Lowe, NJ; Morman, MR; Odom, RB; Pinnell, S; Rich, P; Savin, RC; Scher, RK; Shupack, JL; Smith, EB; Tschen, EH, 1998) |
| "The purpose of this study was to assess the safety and efficacy of oral fluconazole 150, 300, and 450 mg administered once weekly compared with placebo in the treatment of distal subungual onychomycosis of the fingernail caused by dermatophytes." | 5.08 | Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. ( Babel, D; Breneman, D; Bucko, AD; Drake, L; Elewski, BE; Ellis, CN; Greer, DL; Hanifin, JM; Kang, S; Katz, HI; Leyden, JJ; Ling, MR; Martin, AG; McDonald, CJ; Morman, MR; Muglia, J; Pariser, DM; Pariser, RJ; Rich, P; Savin, RC; Scher, RK; Shupack, JL; Stewart, DM; Tschen, EH; Webster, G, 1998) |
| "Determinations of plasma and fingernail concentrations of fluconazole were performed as part of a larger study comparing the safety and efficacy of once-weekly fluconazole (150, 300, and 450 mg) to placebo in the treatment of distal subungual onychomycosis of the fingernails caused by dermatophytes." | 5.08 | Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. ( Babel, D; Breneman, D; Bucko, AD; Drake, L; Elewski, BE; Ellis, CN; Friedman, D; Hanifin, JM; Hilbert, J; Kang, S; Katz, HI; Leyden, JJ; Ling, MR; Martin, AG; McDonald, CJ; Morman, MR; Muglia, J; Pariser, DM; Pariser, RJ; Rich, P; Savin, RC; Scher, RK; Stewart, DM; Tschen, EH; Webster, G, 1998) |
| "Thirty-four patients with collagen diseases suffering from onychomycosis were treated with fluconazole and showed remarkable improvement." | 5.08 | [Effects of fluconazole on onychomycosis in the patients with collagen diseases]. ( Iwamoto, I; Izumi, H; Nawata, Y; Otawa, M; Sueishi, M; Sugiyama, T; Sumida, T; Takabayashi, K; Tanabe, E; Tomioka, H, 1995) |
| "The purpose of this study was to evaluate three different durations of once-weekly fluconazole for the treatment of onychomycosis of the toenail caused by dermatophytes." | 5.08 | Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. ( Asarch, RG; Babel, D; Bergfeld, WF; Cook, J; Drake, L; Eaglstein, WH; Falanga, V; Falo, L; Hanifin, JM; Jarratt, MT; Kalivas, J; Katz, HI; Lebwohl, MG; Leyden, JJ; Ling, MR; Martin, AG; Monroe, EW; Pariser, DM; Pariser, R; Stewart, DM; Swinyer, LJ; Tharp, M; Thiers, BH; Weinstein, GD; Young, MR, 1998) |
| "This systematic review and network meta-analysis compared the efficacy (as per mycological cure) and adverse event rates of three oral antifungal medications in the treatment of dermatophyte toenail onychomycosis, namely terbinafine, itraconazole and fluconazole." | 5.05 | The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. ( Bamimore, MA; Foley, KA; Gupta, AK; Piguet, V; Shear, NH; Stec, N, 2020) |
| "Fluconazole, itraconazole and terbinafine are effective in the treatment of onychomycosis and have a good safety profile." | 4.90 | Oral therapy for onychomycosis: an evidence-based review. ( de Sá, DC; Lamas, AP; Tosti, A, 2014) |
| "Fluconazole could be an alternative to terbinafine and itraconazole for onychomycosis treatment." | 4.89 | Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment. ( Drummond-Main, C; Gupta, AK; Paquet, M, 2013) |
| "To evaluate the efficacy of fluconazole for the treatment of onychomycosis." | 4.85 | Efficacy of fluconazole for the treatment of onychomycosis. ( Brown, SJ, 2009) |
| "Oral antifungal therapy against superficial dermatophytosis and onychomycosis, including intermittent and continuous terbinafine, itraconazole, and fluconazole, was associated with a low incidence of adverse events in an immunocompetent population." | 4.84 | The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. ( Chan, AK; Chang, CH; Kurth, T; Orav, JE; Young-Xu, Y, 2007) |
| "We searched MEDLINE (1966 to November 2002) for relevant studies evaluating the efficacy of the oral antifungal agents terbinafine, itraconazole (pulse or continuous), fluconazole and griseofulvin for treating dermatophyte toenail onychomycosis." | 4.82 | Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. ( Gupta, AK; Johnson, AM; Ryder, JE, 2004) |
| " Oral candidiasis in immunocompromised patients also requires systemic treatment; oral fluconazole and itraconazole oral solution are highly effective in this setting." | 4.81 | Current management of fungal infections. ( Meis, JF; Verweij, PE, 2001) |
| "Recently a novel topical nail lacquer, ciclopirox solution 8%, has been approved for the treatment of onychomycosis." | 4.80 | Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. ( Gupta, AK, 2000) |
| "To review the use of the new oral antifungal agents, itraconazole, terbinafine and fluconazole for the treatment of onychomycosis of the toenails." | 4.80 | The new oral antifungal agents for onychomycosis of the toenails. ( Gupta, AK; Shear, NH, 1999) |
| " Griseofulvin, the only drug approved by the Food and Drug Administration for the systemic treatment of onychomycosis, has a cure rate that seldom exceeds 40%." | 4.79 | The systemic treatment of onychomycosis. ( Wenig, JA, 1995) |
| "Oral griseofulvin has been the first-line drug in the therapy of dermatophyte onychomycosis for many years." | 4.79 | Oral therapeutic agents in fungal nail disease. ( Roberts, DT, 1994) |
| "Problems with the use of griseofulvin and ketoconazole in the treatment of onychomycosis have led to studies of three new oral antifungal drugs to treat this disease: fluconazole, itraconazole, and terbinafine." | 4.79 | Current trends in onychomycosis therapy: a literature review. ( Hecker, D, 1997) |
| "Based on the high clinical suspicion of fungal peritonitis, fluconazole intraperitoneal (IP) was immediately given on the first day in addition to empirical antibiotics, that is, cefazolin and gentamycin IP." | 4.31 | A successful management of fungal peritonitis caused by Rhodotorula glutinis in CAPD patient, coincident with onychomycosis by Penicillium sp: Case report. ( Hustrini, NM; Panggabean, SD, 2023) |
| "It is concluded that the safranal can be successfully used as a safe and potential permeation enhancer to enhance the transungual delivery of fluconazole for the treatment of onychomycosis." | 4.12 | Investigation on utility of some novel terpenes on transungual delivery of fluconazole for the management of onychomycosis. ( Adin, SN; Ali, A; Aqil, M; Gupta, I; Mujeeb, M; Sultana, Y, 2022) |
| ") species in onychomycosis and analyses in vitro susceptibility to fluconazole and itraconazole." | 3.96 | Candida Distribution in Onychomycosis and in vitro Susceptibility to Antifungal Agents. ( Bridžiuvienė, D; Jablonskienė, V; Kiverytė, S; Paškevičius, A; Švedienė, J; Vaitonis, G, 2020) |
| "Fusarium species have emerged as an important human pathogen in skin disease, onychomycosis, keratitis and invasive disease." | 3.85 | Genetic diversity and antifungal susceptibility of Fusarium isolates in onychomycosis. ( Corrêa, C; Fuentefria, AM; Goldani, LZ; Heidrich, D; Rosa, PD; Scroferneker, ML; Vettorato, G, 2017) |
| "The present study aimed to determine prevalences of tinea pedis and onychomycosis, factors predisposing to their development, and antifungal susceptibilities of causative fungal species against fluconazole, itraconazole, and terbinafine in patients with type 2 diabetes mellitus (DM)." | 3.85 | Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey. ( Balta, I; Oz, A; Oz, Y; Qoraan, I, 2017) |
| "In 1996, oral terbinafine joined itraconazole and fluconazole on the short list of systemic medications that could be used to treat onychomycosis (although fluconazole was not approved for this indication by the US Food and Drug Administration [FDA], it was commonly used for this purpose)." | 3.83 | Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action. ( Rosen, T; Stein Gold, LF, 2016) |
| "Onychomycosis caused by Fusarium spp." | 3.81 | Fusarium spp. is able to grow and invade healthy human nails as a single source of nutrients. ( Galletti, J; Grassi, FL; Kioshima-Cotica, ÉS; Negri, M; Svidzinski, TI, 2015) |
| "To evaluate the in vitro antifungal activity of itraconazole, fluconazole, terbinafine and voriconazole against isolates taken from patients with onychomycosis." | 3.76 | In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. ( Bueno, JG; Gallego, M; Martinez, C; Mesa, AC; Sanclemente, G; Zapata, B, 2010) |
| "The aims of this study were to report the high prevalence of onychomycosis by Fusarium spp." | 3.74 | Fusarium spp. as agents of onychomycosis in immunocompetent hosts. ( Guilhermetti, E; Shinobu, CS; Svidzinski, TI; Takahachi, G, 2007) |
| "Using a reference microdilution method, we studied the antifungal susceptibility to voriconazole and fluconazole of 304 clinical isolates from four species of onychomycosis-causing dermatophytes, 196 isolates of dermatophytes not related to nail infection as well as Scopulariopsis brevicaulis, Fusarium spp." | 3.74 | In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. ( Cárdenes, CD; Carrillo-Muñoz, AJ; del Valle, O; Estivill, D; Giusiano, G; Guardia, C; Guarro, J; Quindós, G; Rodríguez, V, 2007) |
| "We aimed to determine the in vitro susceptibility patterns of dermatophytes causing onychomycosis, against the traditionally available systemic antifungal agents terbinafine, itraconazole and fluconazole." | 3.74 | In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium. ( Can, F; Demirbilek, M; Sarifakioglu, E; Seçkin, D, 2007) |
| "A 73-year-old white man taking nitrofurantoin 50 mg/day for 5 years developed combined hepatic and pulmonary toxicity after taking fluconazole acutely for onychomycosis." | 3.72 | Pulmonary and hepatic toxicity due to nitrofurantoin and fluconazole treatment. ( Linnebur, SA; Parnes, BL, 2004) |
| " In a second study, 36 patients with toenail onychomycosis received either fluconazole 150 mg once weekly or griseofulvin 1000 mg once daily for 12 months." | 3.70 | Pharmacokinetics of fluconazole in skin and nails. ( Faergemann, J, 1999) |
| "Our purpose was to evaluate the intermittent use of fluconazole (either once-weekly or alternate-day dosing) without concurrent nail avulsion in patients with moderate to severe onychomycosis." | 3.69 | Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. ( Assaf, RR; Elewski, BE, 1996) |
| "We report a case of fingernail onychomycosis in an immunosuppressed renal transplant patient who was successfully treated with once-weekly fluconazole therapy." | 3.68 | Onychomycosis: successful treatment with once-weekly fluconazole. ( Nahass, GT; Sisto, M, 1993) |
| "Onychomycosis is a fungal infection of the nail unit." | 2.80 | Treatment of Onychomycosis - a Clinical Study. ( Pajaziti, L; Vasili, E, 2015) |
| "Fluconazole was well tolerated and side effects were negligible." | 2.77 | A comparative evaluation of combination therapy of fluconazole 1% and urea 40% compared with fluconazole 1% alone in a nail lacquer for treatment of onychomycosis: therapeutic trial. ( Bassiri-Jahromi, S; Ehsani, AH; Jamshidi, B; Mirshams-Shahshahani, M, 2012) |
| "Onychomycosis is a common fungal disease infecting up to 20% of the population over age 40." | 2.69 | Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail. ( Bradley, MC; Elewski, BE; Ghannoum, MA; Isham, N; Leidich, S, 1999) |
| "Onychomycosis is a fungal infection of the nail, causing discoloration and thickening of the affected nail plate, and is the most common nail infection worldwide." | 2.66 | Onychomycosis: a review. ( Gupta, AK; Piguet, V; Piraccini, BM; Shear, NH; Stec, N; Summerbell, RC; Tosti, A, 2020) |
| "Onychomycosis is a fungal nail infection caused by dermatophytes, nondermatophytes, and yeast, and is the most common nail disorder seen in clinical practice." | 2.61 | Onychomycosis: Treatment and prevention of recurrence. ( Lipner, SR; Scher, RK, 2019) |
| "Onychomycosis is considered an age-related infection with increasing prevalence in the older age groups." | 2.55 | Onychomycosis in children. A review. ( García-Romero, MT; Solís-Arias, MP, 2017) |
| "Onychomycosis is a common superficial fungal infection, which usually caused by dermatophytes, yeast and non-dermatophytic moulds." | 2.50 | Rhodotorula minuta as onychomycosis agent in a Chinese patient: first report and literature review. ( Chen, H; Chen, M; Liao, W; Pan, W; Zhou, J, 2014) |
| "Onychomycosis is a frequent nail disease caused by dermatophytes, yeasts, and nondermatophyte molds." | 2.46 | Onychomycosis. ( Vera-Cabrera, L; Welsh, E; Welsh, O, 2010) |
| "In the treatment of onychomycosis, compliance and drug interactions are important considerations, as diabetic patients frequently take concomitant medications." | 2.45 | Toenail onychomycosis in diabetic patients: issues and management. ( Budihardja, D; Freund, V; Mayser, P, 2009) |
| "Fluconazole has excellent absorption and good persistence in tissues that suggests it may be useful in superficial fungal infections." | 2.42 | The use of fluconazole to treat superficial fungal infections in children. ( Cooper, EA; Gupta, AK; Montero-Gei, F, 2003) |
| "Griseofulvin was the first significant oral agent available to manage onychomycosis." | 2.42 | The use of oral antifungal agents to treat onychomycosis. ( Gupta, AK; Ryder, JE, 2003) |
| "Onychomycosis is a public health concern because of its high world wide prevalence, and its potential for spread of fungal elements to others." | 2.41 | [How to improve efficacy of onychomycosis treatment?]. ( Nowicki, R, 2001) |
| " Intermittent pulse dosing with itraconazole is as safe and effective as short-term continuous therapy but more economical and convenient." | 2.41 | Treating onychomycosis. ( Bassler, M; Rodgers, P, 2001) |
| "Onychomycosis is a common infectious disease." | 2.40 | [Diagnosis, differential diagnosis and therapy of onychomycosis]. ( Seebacher, C, 1998) |
| " In addition, the short treatment times (< 3 months) and intermittent dosing schedules are likely to enhance compliance and reduce the costs of therapy." | 2.40 | Onychomycosis: pathogenesis, diagnosis, and management. ( Elewski, BE, 1998) |
| "The number of patients with tinea unguium accounts for 0." | 2.40 | Current topics in diagnosis and treatment of tinea unguium in Japan. ( Tanuma, H, 1999) |
| "The management of onychomycosis has changed considerably in the past few years." | 2.38 | Onychomycosis. Agents of choice. ( Hay, RJ, 1993) |
| "Neurologic adverse effects of triazole antifungal compounds used for the treatment of systemic and deep mycoses are relatively rare." | 1.62 | Acute fluconazole toxicity: a case presenting with protean manifestations including systemic and neurologic symptoms. ( Ergene, U; Eşkut, N; Gedizlioğlu, M; Özlü, C; Ünal, O, 2021) |
| "Onychomycosis is most commonly caused by dermatophytes." | 1.51 | Diversity of phenotypically non-dermatophyte, non-Aspergillus filamentous fungi causing nail infections: importance of accurate identification and antifungal susceptibility testing. ( Chan, JFW; Chan, KF; Cheung, M; Fung, KSC; Lai, CKC; Lau, ECL; Lau, SKP; Lee, CY; Li, X; Ng, RHY; Ngan, AHY; Tang, JYM; Tsang, CC; Woo, PCY, 2019) |
| "Fluconazole (100 mg/day) was administered from April 8, 2006." | 1.35 | [A case of nail candidiasis with severe deformities treated with oral fluconazole]. ( Ito, Y; Kobayashi, M; Sei, Y; Soude, E; Sukegawa, N; Takahashi, E, 2008) |
| "Onychomycosis is a common adult human mycosis, and dermatophytes of the Trichophyton genera are the most common causative agent." | 1.34 | Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A). ( Barros, MEDS; Hamdan, JS; Santos, DA, 2007) |
| "The successful treatment of onychomycosis requires special knowledge of the various clinical presentations, of the differential diagnosis and of recent advances in medical mycology." | 1.32 | [Onychomycosis]. ( Reinel, D, 2004) |
| "Sertaconazole was active against 114 isolates of 12 fungal dermatophyte species, showing an overall geometric mean of 0." | 1.32 | In vitro activity of sertaconazole against dermatophyte isolates with reduced fluconazole susceptibility. ( Cárdenes, DC; Carrillo-Muñoz, AJ; Fernández-Torres, B; Guarro, J, 2003) |
| "Fluconazole (Fungolon) has only been recently used in the treatment of nail fungal infections." | 1.32 | Fluconazole (Fungolon) in the treatment of onychomycoses. ( Zisova, LG, 2004) |
| "Pediatric onychomycosis is a rare disease and it is difficult to decide in such cases whether or not an oral antifungal is indicated." | 1.30 | [Pediatric onychomycosis treated with oral antifungal drugs]. ( Hiruma, M; Kawai, M; Maeng, DJ; Ogawa, H; Takimoto, R, 1999) |
| "Until recently, the treatment of onychomycosis was discouraging because of the relatively low success rate, the need for prolonged therapy, and the laboratory monitoring necessary with the traditional oral antifungal agents, griseofulvin and ketoconazole." | 1.29 | New therapies for onychomycosis. ( Odom, RB, 1996) |
| " An adverse function questionnaire was used on a monthly basis to assess patient tolerance." | 1.29 | An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. ( Lackland, D; Schneider, E; Sealy, DP; Smith, SW, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 40 (35.09) | 18.2507 |
| 2000's | 46 (40.35) | 29.6817 |
| 2010's | 22 (19.30) | 24.3611 |
| 2020's | 6 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Adin, SN | 1 |
| Gupta, I | 1 |
| Ali, A | 1 |
| Aqil, M | 1 |
| Mujeeb, M | 1 |
| Sultana, Y | 1 |
| Panggabean, SD | 1 |
| Hustrini, NM | 1 |
| Gupta, AK | 12 |
| Stec, N | 2 |
| Bamimore, MA | 1 |
| Foley, KA | 1 |
| Shear, NH | 3 |
| Piguet, V | 2 |
| Summerbell, RC | 1 |
| Tosti, A | 2 |
| Piraccini, BM | 1 |
| Eşkut, N | 1 |
| Gedizlioğlu, M | 1 |
| Ünal, O | 1 |
| Özlü, C | 1 |
| Ergene, U | 1 |
| Paškevičius, A | 1 |
| Švedienė, J | 1 |
| Kiverytė, S | 1 |
| Bridžiuvienė, D | 1 |
| Vaitonis, G | 1 |
| Jablonskienė, V | 1 |
| Rosa, PD | 1 |
| Heidrich, D | 1 |
| Corrêa, C | 1 |
| Scroferneker, ML | 1 |
| Vettorato, G | 1 |
| Fuentefria, AM | 1 |
| Goldani, LZ | 1 |
| Nenoff, P | 2 |
| Krüger, C | 1 |
| Schulze, I | 1 |
| Koch, D | 1 |
| Rahmig, N | 1 |
| Hipler, UC | 1 |
| Uhrlaß, S | 1 |
| Liang, SE | 1 |
| Cohen, DE | 1 |
| Rieder, EA | 1 |
| Lipner, SR | 2 |
| Scher, RK | 7 |
| Lin, K | 1 |
| Tsang, CC | 1 |
| Tang, JYM | 1 |
| Chan, KF | 1 |
| Lee, CY | 1 |
| Chan, JFW | 1 |
| Ngan, AHY | 1 |
| Cheung, M | 1 |
| Lau, ECL | 1 |
| Li, X | 1 |
| Ng, RHY | 1 |
| Lai, CKC | 1 |
| Fung, KSC | 1 |
| Lau, SKP | 1 |
| Woo, PCY | 1 |
| Zhou, J | 1 |
| Chen, M | 1 |
| Chen, H | 1 |
| Pan, W | 1 |
| Liao, W | 1 |
| de Sá, DC | 1 |
| Lamas, AP | 1 |
| Hryncewicz-Gwóźdź, A | 1 |
| Plomer-Niezgoda, E | 1 |
| Kalinowska, K | 1 |
| Czarnecka, A | 1 |
| Maj, J | 1 |
| Jagielski, T | 1 |
| Galletti, J | 1 |
| Negri, M | 1 |
| Grassi, FL | 1 |
| Kioshima-Cotica, ÉS | 1 |
| Svidzinski, TI | 2 |
| Pajaziti, L | 1 |
| Vasili, E | 1 |
| Seidl, HP | 1 |
| Jäckel, A | 1 |
| Müller, J | 1 |
| Schaller, M | 1 |
| Borelli, C | 1 |
| Polak, A | 1 |
| Rosen, T | 1 |
| Stein Gold, LF | 1 |
| Solís-Arias, MP | 1 |
| García-Romero, MT | 1 |
| Oz, Y | 1 |
| Qoraan, I | 1 |
| Oz, A | 1 |
| Balta, I | 1 |
| Carrillo-Muñoz, AJ | 3 |
| Quindós, G | 2 |
| Del Valle, O | 2 |
| Santos, P | 1 |
| Giusiano, G | 2 |
| Guardia, C | 2 |
| Eraso, E | 1 |
| Ezkurra, PA | 1 |
| Tur-Tur, C | 1 |
| Hernández-Molina, JM | 1 |
| Kobayashi, M | 1 |
| Soude, E | 1 |
| Takahashi, E | 1 |
| Sukegawa, N | 1 |
| Sei, Y | 1 |
| Ito, Y | 1 |
| Mayser, P | 1 |
| Freund, V | 1 |
| Budihardja, D | 1 |
| Brown, SJ | 1 |
| Bueno, JG | 1 |
| Martinez, C | 1 |
| Zapata, B | 1 |
| Sanclemente, G | 1 |
| Gallego, M | 1 |
| Mesa, AC | 1 |
| Baudraz-Rosselet, F | 1 |
| Ruffieux, C | 1 |
| Lurati, M | 1 |
| Bontems, O | 1 |
| Monod, M | 1 |
| Welsh, O | 1 |
| Vera-Cabrera, L | 1 |
| Welsh, E | 1 |
| Bassiri-Jahromi, S | 1 |
| Ehsani, AH | 1 |
| Mirshams-Shahshahani, M | 1 |
| Jamshidi, B | 1 |
| Drummond-Main, C | 1 |
| Paquet, M | 1 |
| Khosravi, AR | 1 |
| Shokri, H | 1 |
| Nikaein, D | 1 |
| Mansouri, P | 1 |
| Erfanmanesh, A | 1 |
| Chalangari, R | 1 |
| Katalin, M | 1 |
| Tchernev, G | 1 |
| Penev, PK | 1 |
| Zisova, LG | 2 |
| Cardoso, JC | 1 |
| Taneva, T | 1 |
| Ginter-Hanselmayer, G | 1 |
| Ananiev, J | 1 |
| Gulubova, M | 1 |
| Hristova, R | 1 |
| Nocheva, D | 1 |
| Guarneri, C | 1 |
| Martino, G | 1 |
| Kanazawa, N | 1 |
| Glad'ko, VV | 1 |
| Tarasenko, GN | 1 |
| Otto, K | 1 |
| Ryder, JE | 2 |
| Cooper, EA | 1 |
| Montero-Gei, F | 2 |
| Fernández-Torres, B | 1 |
| Cárdenes, DC | 1 |
| Guarro, J | 2 |
| Linnebur, SA | 1 |
| Parnes, BL | 1 |
| Reinel, D | 1 |
| Seebacher, C | 2 |
| Johnson, AM | 1 |
| Goel, A | 1 |
| Jain, C | 1 |
| Rao, R | 1 |
| Shenoi, SD | 1 |
| Chen, X | 1 |
| Hiruma, M | 3 |
| Shiraki, Y | 1 |
| Ogawa, H | 2 |
| Baran, R | 2 |
| Coquard, F | 1 |
| Negroni, R | 1 |
| Tuculet, MA | 1 |
| Crawford, F | 2 |
| Ferrari, J | 2 |
| El-Komy, MH | 1 |
| Nowicki, R | 1 |
| El Euch, D | 1 |
| Bouassida, S | 1 |
| Kourda, M | 1 |
| Ezzine, N | 1 |
| Denguezli, M | 1 |
| Mokhtar, I | 1 |
| Doss, N | 1 |
| Turki, H | 1 |
| Ridha Kamoun, M | 1 |
| Nouira, R | 1 |
| Ben Osman Dhahril, A | 1 |
| Barros, MEDS | 1 |
| Santos, DA | 1 |
| Hamdan, JS | 2 |
| Bonifaz, A | 1 |
| Paredes, V | 1 |
| Fierro, L | 1 |
| Figueiredo, VT | 1 |
| de Assis Santos, D | 1 |
| Resende, MA | 1 |
| Rodríguez, V | 1 |
| Estivill, D | 1 |
| Cárdenes, CD | 1 |
| Guilhermetti, E | 1 |
| Takahachi, G | 1 |
| Shinobu, CS | 1 |
| Sarifakioglu, E | 1 |
| Seçkin, D | 1 |
| Demirbilek, M | 1 |
| Can, F | 1 |
| Chang, CH | 1 |
| Young-Xu, Y | 1 |
| Kurth, T | 1 |
| Orav, JE | 1 |
| Chan, AK | 1 |
| Méndez-Tovar, LJ | 1 |
| Manzano-Gayosso, P | 1 |
| Velásquez-Hernández, V | 1 |
| Millan-Chiu, B | 1 |
| Hernández-Hernández, F | 1 |
| Mondragón-González, R | 1 |
| López-Martínez, R | 1 |
| Smith, SW | 1 |
| Sealy, DP | 1 |
| Schneider, E | 1 |
| Lackland, D | 1 |
| Wenig, JA | 1 |
| Takabayashi, K | 1 |
| Nawata, Y | 1 |
| Sumida, T | 1 |
| Izumi, H | 1 |
| Otawa, M | 1 |
| Iwamoto, I | 1 |
| Tanabe, E | 1 |
| Tomioka, H | 1 |
| Sugiyama, T | 1 |
| Sueishi, M | 1 |
| Roberts, DT | 1 |
| Hay, RJ | 1 |
| Nahass, GT | 1 |
| Sisto, M | 1 |
| Phillips, P | 1 |
| Assaf, RR | 1 |
| Elewski, BE | 9 |
| Kalivas, J | 2 |
| Odom, RB | 3 |
| Faergemann, J | 2 |
| Laufen, H | 2 |
| Robles-Soto, ME | 1 |
| Schlager, H | 1 |
| Suarez, S | 1 |
| Piérard, GE | 3 |
| Del Rosso, JQ | 2 |
| Hecker, D | 1 |
| Joseph, WS | 1 |
| Hernanz Hermosa, JM | 1 |
| Lázaro Ochaita, P | 1 |
| Breneman, D | 4 |
| Rich, P | 5 |
| Savin, RC | 4 |
| Feingold, DS | 2 |
| Konnikov, N | 2 |
| Shupack, JL | 3 |
| Pinnell, S | 2 |
| Levine, N | 2 |
| Lowe, NJ | 2 |
| Aly, R | 2 |
| Greer, DL | 3 |
| Morman, MR | 4 |
| Bucko, AD | 4 |
| Tschen, EH | 4 |
| Smith, EB | 2 |
| Drake, L | 3 |
| Babel, D | 3 |
| Stewart, DM | 3 |
| Ling, MR | 3 |
| Martin, AG | 3 |
| Pariser, DM | 3 |
| Pariser, RJ | 2 |
| Ellis, CN | 2 |
| Kang, S | 2 |
| Katz, HI | 3 |
| McDonald, CJ | 2 |
| Muglia, J | 2 |
| Webster, G | 2 |
| Leyden, JJ | 3 |
| Hanifin, JM | 3 |
| Swinyer, LJ | 1 |
| Jarratt, MT | 1 |
| Falo, L | 1 |
| Monroe, EW | 1 |
| Tharp, M | 1 |
| Weinstein, GD | 1 |
| Asarch, RG | 1 |
| Cook, J | 1 |
| Pariser, R | 1 |
| Thiers, BH | 1 |
| Lebwohl, MG | 1 |
| Eaglstein, WH | 1 |
| Falanga, V | 1 |
| Bergfeld, WF | 1 |
| Young, MR | 1 |
| Hilbert, J | 2 |
| Friedman, D | 1 |
| Kar, HK | 1 |
| Maeng, DJ | 1 |
| Takimoto, R | 1 |
| Kawai, M | 1 |
| Wolf, R | 1 |
| Wolf, D | 1 |
| Ruocco, V | 1 |
| Tanuma, H | 1 |
| Zimmermann, T | 1 |
| Yeates, RA | 1 |
| Schumacher, T | 1 |
| Wildfeuer, A | 1 |
| Arrese, JE | 2 |
| Piérard-Franchimont, C | 2 |
| Lambert, J | 1 |
| Havu, V | 1 |
| Heikkilä, H | 1 |
| Kuokkanen, K | 1 |
| Nuutinen, M | 1 |
| Rantanen, T | 1 |
| Saari, S | 1 |
| Stubb, S | 1 |
| Suhonen, R | 1 |
| Turjanmaa, K | 1 |
| Niewerth, M | 1 |
| Korting, HC | 1 |
| Bradley, MC | 1 |
| Leidich, S | 1 |
| Isham, N | 1 |
| Ghannoum, MA | 1 |
| Tseng, SS | 1 |
| Longley, BJ | 1 |
| Treiber, RK | 1 |
| Meis, JF | 1 |
| Verweij, PE | 1 |
| Rodgers, P | 1 |
| Bassler, M | 1 |
| Hattori, A | 1 |
| Iida, T | 1 |
| Nishiyama, C | 1 |
| Gregurek-Novak, T | 1 |
| Salo, H | 1 |
| Pekurinen, M | 1 |
| Arca, E | 1 |
| Taştan, HB | 1 |
| Akar, A | 1 |
| Kurumlu, Z | 1 |
| Gür, AR | 1 |
| Fukuda, T | 1 |
| Coldiron, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis[NCT03171584] | Phase 3 | 60 participants (Anticipated) | Interventional | 2017-07-01 | Not yet recruiting | ||
| Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study[NCT03814343] | Phase 4 | 19 participants (Actual) | Interventional | 2019-01-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
43 reviews available for fluconazole and Nail Fungus
| Article | Year |
|---|---|
The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Fluconazole; Humans; Itraconazole; Onychomycosis; Terbinafi | 2020 |
Onychomycosis: a review.
Topics: Administration, Topical; Antifungal Agents; Fluconazole; Humans; Itraconazole; Onychomycosis; Terbin | 2020 |
[Tinea capitis and onychomycosis due to Trichophyton soudanense : Successful treatment with fluconazole-literature review].
Topics: Antifungal Agents; Child; Dermatomycoses; Europe; Female; Fluconazole; Germany; Humans; Onychomycosi | 2018 |
Proximal Subungual Onychomycosis in the Immunocompetent: A Case Report and Review of the Literature.
Topics: Administration, Oral; Antifungal Agents; Fluconazole; Foot Dermatoses; Humans; Immunocompetence; Mal | 2018 |
Onychomycosis: Treatment and prevention of recurrence.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Fluconazole | 2019 |
Rhodotorula minuta as onychomycosis agent in a Chinese patient: first report and literature review.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Asian People; China; Drug Resistance, Fungal; Female; | 2014 |
Oral therapy for onychomycosis: an evidence-based review.
Topics: Administration, Oral; Antifungal Agents; Clinical Trials as Topic; Fluconazole; Humans; Itraconazole | 2014 |
Onychomycosis in children. A review.
Topics: Administration, Oral; Administration, Topical; Adolescent; Antifungal Agents; Child; Child, Preschoo | 2017 |
Toenail onychomycosis in diabetic patients: issues and management.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Ciclopirox; Comorbidity; Diabetes | 2009 |
Efficacy of fluconazole for the treatment of onychomycosis.
Topics: Antifungal Agents; Arthrodermataceae; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fl | 2009 |
Onychomycosis.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Ciclopirox; Drug Administration | 2010 |
Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment.
Topics: Administration, Oral; Antifungal Agents; Arthrodermataceae; Candida; Female; Fluconazole; Humans; Ma | 2013 |
Onychomycosis: modern diagnostic and treatment approaches.
Topics: Antifungal Agents; Candidiasis; Combined Modality Therapy; Dermatomycoses; DNA, Fungal; Enzyme-Linke | 2013 |
The use of oral antifungal agents to treat onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Drug Interactions; Fluconazole; Griseofulvin; Humans; Itrac | 2003 |
The use of fluconazole to treat superficial fungal infections in children.
Topics: Administration, Oral; Antifungal Agents; Child; Child Welfare; Drug Administration Schedule; Flucona | 2003 |
Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.
Topics: Antifungal Agents; Fluconazole; Griseofulvin; Humans; Itraconazole; Naphthalenes; Onychomycosis; Ran | 2004 |
Acrokeratosis paraneoplastica (Bazex syndrome): an atypical presentation.
Topics: Adenocarcinoma; Antifungal Agents; Fluconazole; Foot Dermatoses; Hand Dermatoses; Humans; Hyperpigme | 2004 |
Fungal nail infections.
Topics: Antifungal Agents; Fluconazole; Griseofulvin; Humans; Itraconazole; Ketoconazole; Naphthalenes; Onyc | 2005 |
[Onychomycosis: recent progress in the epidemiology, diagnosis and treatment].
Topics: Administration, Topical; Antifungal Agents; Fluconazole; Foot Dermatoses; Hand Dermatoses; Humans; I | 2006 |
[How to improve efficacy of onychomycosis treatment?].
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifungal Agents; Dermatomycoses; Drug Therapy, C | 2001 |
Fungal toenail infections.
Topics: Antifungal Agents; Fluconazole; Griseofulvin; Humans; Itraconazole; Ketoconazole; Naphthalenes; Onyc | 2006 |
The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis.
Topics: Antifungal Agents; Dermatomycoses; Fluconazole; Humans; Itraconazole; Liver Function Tests; Models, | 2007 |
The systemic treatment of onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Fluconazole; Foot Dermatoses; Griseofulvin; Humans; Itracon | 1995 |
Oral therapeutic agents in fungal nail disease.
Topics: Administration, Oral; Allylamine; Antifungal Agents; Fluconazole; Griseofulvin; Humans; Itraconazole | 1994 |
Onychomycosis. Agents of choice.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Candidiasis, Cutaneous; Fluconaz | 1993 |
New antifungal therapy for children.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Child; Dermatomycoses; Drug Inte | 1997 |
Current trends in onychomycosis therapy: a literature review.
Topics: Antifungal Agents; Fluconazole; Humans; Itraconazole; Ketoconazole; Naphthalenes; Onychomycosis; Ter | 1997 |
Oral treatment options for onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Drug Interactions; Fluconazole; Foot Dermatoses; Humans; It | 1997 |
[Superficial mycoses in immunosuppressed patients].
Topics: Adult; Antifungal Agents; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Chil | 1995 |
[Diagnosis, differential diagnosis and therapy of onychomycosis].
Topics: Administration, Topical; Antifungal Agents; Diagnosis, Differential; Drug Administration Schedule; F | 1998 |
Once-weekly fluconazole in the treatment of onychomycosis: introduction.
Topics: Administration, Oral; Antifungal Agents; Clinical Trials as Topic; Fluconazole; Foot Dermatoses; Han | 1998 |
Onychomycosis: pathogenesis, diagnosis, and management.
Topics: Adult; Antifungal Agents; Child; Diagnosis, Differential; Female; Fluconazole; Foot Dermatoses; Hand | 1998 |
Fluconazole for the treatment of onychomycosis: an update.
Topics: Antifungal Agents; Clinical Trials as Topic; Fluconazole; Humans; Onychomycosis; Treatment Outcome | 1998 |
Current topics in diagnosis and treatment of tinea unguium in Japan.
Topics: Administration, Oral; Aged; Antifungal Agents; Diagnosis, Differential; Female; Fluconazole; Griseof | 1999 |
Facing up to the diagnostic uncertainty and management of onychomycoses.
Topics: Antifungal Agents; Fluconazole; Humans; Itraconazole; Naphthalenes; Onychomycosis; Terbinafine | 1999 |
Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA.
Topics: Administration, Oral; Antifungal Agents; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutica | 1999 |
The new oral antifungal agents for onychomycosis of the toenails.
Topics: Administration, Oral; Antifungal Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 1999 |
An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents.
Topics: Administration, Oral; Antifungal Agents; Clinical Trials as Topic; Dermatomycoses; Drug Administrati | 2000 |
Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Arthrodermataceae; Ciclopirox; Cos | 2000 |
Current management of fungal infections.
Topics: Administration, Oral; Administration, Topical; Amphotericin B; Antifungal Agents; Aspergillosis; Can | 2001 |
Treating onychomycosis.
Topics: Adult; Antifungal Agents; Child; Clinical Trials as Topic; Combined Modality Therapy; Diagnosis, Dif | 2001 |
[A case of Folliculitis barbae Candidomycetica].
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Candidiasis, Cutaneous; Diagnosis, Differentia | 2001 |
A plea to bridge the gap between antifungals and the management of onychomycosis.
Topics: Antifungal Agents; Fluconazole; Humans; Itraconazole; Ketoconazole; Naphthalenes; Onychomycosis; Ter | 2001 |
20 trials available for fluconazole and Nail Fungus
| Article | Year |
|---|---|
Efficacy of fluconazole at a 400 mg weekly dose for the treatment of onychomycosis.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Drug Administration Schedule; Female; Fluconazole; Foot | 2015 |
Treatment of Onychomycosis - a Clinical Study.
Topics: Antifungal Agents; Ciclopirox; Drug Administration Schedule; Drug Therapy, Combination; Fluconazole; | 2015 |
A comparative evaluation of combination therapy of fluconazole 1% and urea 40% compared with fluconazole 1% alone in a nail lacquer for treatment of onychomycosis: therapeutic trial.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Double-Blind Method; Drug Combinations; Fem | 2012 |
Combination therapy of once-weekly fluconazole (100, 150, or 300 mg) with topical application of ketoconazole cream in the treatment of onychomycosis.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aged, 80 and over; Antifungal Agents; Do | 2004 |
Nailfold fluconazole fluid injection for fingernail onychomycosis.
Topics: Antifungal Agents; Fluconazole; Hand Dermatoses; Humans; Injections; Onychomycosis | 2006 |
[Fluconazole and treatment of onychomycosis. About 86 cases].
Topics: Adolescent; Adult; Aged; Antifungal Agents; Female; Fluconazole; Follow-Up Studies; Foot Dermatoses; | 2006 |
[Effects of fluconazole on onychomycosis in the patients with collagen diseases].
Topics: Adult; Collagen Diseases; Female; Fluconazole; Humans; Male; Middle Aged; Onychomycosis; Opportunist | 1995 |
Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toe-nails with fluconazole 150 mg once weekly.
Topics: Antifungal Agents; Double-Blind Method; Fluconazole; Griseofulvin; Humans; Nails; Onychomycosis; Tim | 1996 |
Fluconazole in the treatment of severe onychomycosis.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antifungal Agents; Arthrodermataceae; Female; Fluconazole; | 1996 |
Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Arthrodermataceae; Dose-Response Relationship, Drug; Dou | 1998 |
Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Arthrodermataceae; Dose-Response Relationship, Drug; Dou | 1998 |
Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Arthrodermataceae; Dose-Response Relationship, Drug; Dou | 1998 |
Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail.
Topics: Antifungal Agents; Double-Blind Method; Drug Administration Schedule; Female; Fluconazole; Foot Derm | 1998 |
Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail.
Topics: Adult; Aged; Antifungal Agents; Drug Administration Schedule; Female; Fluconazole; Hand Dermatoses; | 1998 |
The uptake of fluconazole in finger and toe nails.
Topics: Adolescent; Adult; Antifungal Agents; Chromatography, Gas; Female; Fluconazole; Humans; Male; Middle | 1999 |
A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Fluconazole; Humans; Middle Aged; N | 2000 |
Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail.
Topics: Adult; Antifungal Agents; Female; Fluconazole; Foot Dermatoses; Griseofulvin; Humans; Itraconazole; | 1999 |
Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
Topics: Adult; Antifungal Agents; Female; Fluconazole; Follow-Up Studies; Foot Dermatoses; Gastrointestinal | 2001 |
Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis.
Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Cost-Benefit Analysis; Double-Blind Method; Fe | 2002 |
An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents; Female; Fluconazole; Humans; Itrac | 2002 |
51 other studies available for fluconazole and Nail Fungus
| Article | Year |
|---|---|
Investigation on utility of some novel terpenes on transungual delivery of fluconazole for the management of onychomycosis.
Topics: Administration, Topical; Fluconazole; Humans; Limonene; Nails; Onychomycosis; Permeability; Terpenes | 2022 |
A successful management of fungal peritonitis caused by Rhodotorula glutinis in CAPD patient, coincident with onychomycosis by Penicillium sp: Case report.
Topics: Adult; Dialysis Solutions; Fluconazole; Humans; Male; Mycoses; Onychomycosis; Peritoneal Dialysis, C | 2023 |
Acute fluconazole toxicity: a case presenting with protean manifestations including systemic and neurologic symptoms.
Topics: Acute Kidney Injury; Antifungal Agents; Confusion; Drug-Related Side Effects and Adverse Reactions; | 2021 |
Candida Distribution in Onychomycosis and in vitro Susceptibility to Antifungal Agents.
Topics: Antifungal Agents; Candida; Fluconazole; Humans; Microbial Sensitivity Tests; Onychomycosis | 2020 |
Genetic diversity and antifungal susceptibility of Fusarium isolates in onychomycosis.
Topics: Amphotericin B; Antifungal Agents; Female; Fluconazole; Fusariosis; Fusarium; Genetic Variation; Hum | 2017 |
Mobile phone reminders for onychomycosis medication adherence.
Topics: Antifungal Agents; Cell Phone; Drug Administration Schedule; Fluconazole; Humans; Medication Adheren | 2019 |
Diversity of phenotypically non-dermatophyte, non-Aspergillus filamentous fungi causing nail infections: importance of accurate identification and antifungal susceptibility testing.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Biodiversity; Child; Child, Preschool; Female; Fluconazo | 2019 |
Fusarium spp. is able to grow and invade healthy human nails as a single source of nutrients.
Topics: Antifungal Agents; Cross-Sectional Studies; Fluconazole; Fusariosis; Fusarium; Humans; Keratins; Mic | 2015 |
Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections.
Topics: Antifungal Agents; Candida albicans; Ciclopirox; Epidermophyton; Fluconazole; Hand Dermatoses; Human | 2015 |
Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Boron Compounds; Bridged Bicyclo | 2016 |
Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey.
Topics: Adult; Age Factors; Aged; Antifungal Agents; Arthrodermataceae; Case-Control Studies; Diabetes Melli | 2017 |
In vitro antifungal activity of sertaconazole nitrate against recent isolates of onychomycosis causative agents.
Topics: Antifungal Agents; Arthrodermataceae; Ciclopirox; Dose-Response Relationship, Drug; Fluconazole; Fun | 2008 |
[A case of nail candidiasis with severe deformities treated with oral fluconazole].
Topics: Administration, Oral; Aged; Candidiasis; Female; Fluconazole; Humans; Nails, Malformed; Onychomycosi | 2008 |
In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Topics: Analysis of Variance; Antifungal Agents; Arthrodermataceae; Candida; Colombia; Dose-Response Relatio | 2010 |
Onychomycosis insensitive to systemic terbinafine and azole treatments reveals non-dermatophyte moulds as infectious agents.
Topics: Acremonium; Adult; Antifungal Agents; Aspergillus; Female; Fluconazole; Foot Dermatoses; Fusarium; H | 2010 |
Yeasts as important agents of onychomycosis: in vitro activity of propolis against yeasts isolated from patients with nail infection.
Topics: Adolescent; Adult; Antifungal Agents; Apitherapy; Child; Child, Preschool; Drug Resistance; Fluconaz | 2013 |
[Pharmacoeconomic approach to onychomycosis therapy].
Topics: Antifungal Agents; Fluconazole; Humans; Itraconazole; Military Personnel; Naphthalenes; Onychomycosi | 2002 |
[Therapy of onychomycosis. The package insert states otherwise].
Topics: Administration, Oral; Antifungal Agents; Dose-Response Relationship, Drug; Drug Administration Sched | 2002 |
In vitro activity of sertaconazole against dermatophyte isolates with reduced fluconazole susceptibility.
Topics: Antifungal Agents; Arthrodermataceae; Drug Resistance, Fungal; Fluconazole; Imidazoles; Microbial Se | 2003 |
Pulmonary and hepatic toxicity due to nitrofurantoin and fluconazole treatment.
Topics: Aged; Antifungal Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Fluconaz | 2004 |
[Onychomycosis].
Topics: Antifungal Agents; Ciclopirox; Debridement; Diagnosis, Differential; Drug Therapy, Combination; Fluc | 2004 |
[Modern antimycotics. What the treating physician needs to know].
Topics: Antifungal Agents; Arthrodermataceae; Child; Dermatomycoses; Fluconazole; Griseofulvin; Humans; Itra | 2004 |
Fluconazole induced fixed drug eruption: a rare offender.
Topics: Antifungal Agents; Drug Eruptions; Fluconazole; Humans; Onychomycosis | 2004 |
Fluconazole (Fungolon) in the treatment of onychomycoses.
Topics: Adult; Aged; Antifungal Agents; Female; Fluconazole; Foot Dermatoses; Hand Dermatoses; Humans; Male; | 2004 |
Combination of fluconazole and urea in a nail lacquer for treating onychomycosis.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Drug Therapy, Combination; Female; Fluconaz | 2005 |
[Clinical cases in medical mycology. Case No. 16].
Topics: Adolescent; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Blood Sedimen | 2005 |
Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A).
Topics: Antifungal Agents; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Fluconazole; Humans; I | 2007 |
Onychocryptosis as consequence of effective treatment of dermatophytic onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Drug Therapy, Combination; Fluconazole; Humans; Itraconazol | 2007 |
Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections.
Topics: Antifungal Agents; Brazil; Candida; Candidiasis; Ciclopirox; Fluconazole; Hand Dermatoses; Humans; I | 2007 |
In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis.
Topics: Antifungal Agents; Arthrodermataceae; Drug Resistance, Multiple, Fungal; Fluconazole; Humans; Microb | 2007 |
Fusarium spp. as agents of onychomycosis in immunocompetent hosts.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Brazil; Female; Fluconazole; Foot Dermatoses; Fusari | 2007 |
In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
Topics: Adult; Antifungal Agents; Dose-Response Relationship, Drug; Drug Evaluation; Drug Resistance, Fungal | 2007 |
[Resistance to azolic compounds in clinical Trichophyton spp. strains].
Topics: Adult; Antifungal Agents; Cross Infection; Drug Resistance, Fungal; Drug Resistance, Multiple, Funga | 2007 |
An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis.
Topics: Adult; Aged; Antifungal Agents; Female; Fluconazole; Humans; Male; Middle Aged; Onychomycosis; Treat | 1995 |
Onychomycosis: successful treatment with once-weekly fluconazole.
Topics: Drug Administration Schedule; Female; Fluconazole; Follow-Up Studies; Hand Dermatoses; Humans; Immun | 1993 |
New drugs for the nail fungus prevalent in elderly.
Topics: Aged; Antifungal Agents; Fluconazole; Humans; Itraconazole; Naphthalenes; Onychomycosis; Terbinafine | 1996 |
Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antifun | 1996 |
Thrombocytopenia caused by fluconazole.
Topics: Antifungal Agents; Fluconazole; HIV Infections; Humans; Onychomycosis; Thrombocytopenia | 1996 |
New therapies for onychomycosis.
Topics: Antifungal Agents; Fluconazole; Humans; Itraconazole; Naphthalenes; Onychomycosis; Terbinafine | 1996 |
[How I treat onychomycosis using pulsed therapy].
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Diagnosis, Differential; Drug Ad | 1997 |
Bacterial infection in a patient with onychomycosis.
Topics: Anti-Infective Agents; Antifungal Agents; Ciprofloxacin; Fluconazole; Humans; Male; Middle Aged; Nai | 1997 |
Contempo 1997: dermatology.
Topics: Antifungal Agents; Contraceptives, Oral; Drug Interactions; Fluconazole; Humans; Itraconazole; Napht | 1997 |
Longitudinal melanonychia associated with fluconazole therapy.
Topics: Adult; Antifungal Agents; Fluconazole; Humans; Nail Diseases; Onychomycosis; Pigmentation Disorders | 1998 |
[Pediatric onychomycosis treated with oral antifungal drugs].
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Female; Fluconazole; Humans; Itraconazole | 1999 |
Antifungal sponsored supplements.
Topics: Antifungal Agents; Biological Availability; Fluconazole; Humans; Onychomycosis; Peer Review, Researc | 1999 |
Pharmacokinetics of fluconazole in skin and nails.
Topics: Administration, Oral; Adult; Antifungal Agents; Fluconazole; Griseofulvin; Humans; Male; Nails; Onyc | 1999 |
The use of systemic antimycotics in dermatotherapy.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Cost-Benefit Analysis; Dermatomy | 2000 |
Fusarium fingernail infection responsive to fluconazole intermittent therapy.
Topics: Adult; Antifungal Agents; Drug Administration Schedule; Female; Fluconazole; Fusarium; Hand Dermatos | 2000 |
[Diversified treatments of Tinea unguium].
Topics: Administration, Oral; Antifungal Agents; Combined Modality Therapy; Fluconazole; Griseofulvin; Human | 2002 |
[New treatments of onychomycoses].
Topics: Administration, Topical; Antifungal Agents; Candidiasis; Ciclopirox; Fluconazole; Foot Dermatoses; H | 1992 |
Recalcitrant onychomycosis of the toenails successfully treated with fluconazole.
Topics: Administration, Oral; Adult; Female; Fluconazole; Humans; Male; Onychomycosis; Recurrence | 1992 |